Prevalence of steatotic liver disease and associated fibrosis in the United States: Results from NHANES 2017-March 2020

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder globally, affecting approximately one-quarter of the world's population.1 Recently, a Delphi conference conducted by multiple societies put forth a proposition to rechristen NAFLD as steatotic liver disease (SLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). This endeavor seeks to better reflect the evolving understanding of the disease and ameliorate any stigma attached to it.2 The current study aims to assess the prevalence of various subtypes of SLD and the risk of fibrosis progression, comparing them with NAFLD.